The Pfizer Corona Vaccine Candidate promotes success with up to 90% efficacy, far higher than the typical efficacy of the seasonal flu vaccine, which was 29% effective in the 2018-2019 flu season, according to the CDC.
The Centers for Disease Control and Prevention (CDC) data showed that in the 2015-2016 season, the influenza vaccine was 48% effective, but that number has steadily decreased to 40% in 2016-2017, 38% in 2017-2018 and 29% in 2018-2019.
Preliminary figures for the 2019-2020 flu season showed that the last vaccine was 39% effective.These numbers mean that only 39% of people who were vaccinated in 2019-2020 did not catch the flu.
According to the report of the American newspaper “NY Post”, with the new coronavirus vaccine “Corona”, which is produced by Pfizer, with an effective rate of 90%, this means that the overwhelming majority of those who got the vaccine ended up developing protective antibodies to them. Within 28 days, that will protect at least temporarily the infection.
A recent study, which is awaiting peer review, stated that the antibody immunity lasts at least 6 months, and scientists are already investigating whether the Corona vaccine should be done annually like the influenza vaccine, NBC reported.
Although no vaccine is currently ready on the market for COVID-19, Pfizer expects to have 50 million doses of the BNT162b2 vaccine ready by the end of 2020 and as many as 1.3 billion doses available in 2021.
The efficacy rate of the vaccine has reached 90%, which is much higher than the 50% required for the Coronavirus vaccine by the Food and Drug Administration, and gradually approaches the high levels of immunity provided by the measles and polio vaccine.
The company said that the Pfizer coronavirus vaccine currently requires two booster doses.